Cisplatin a traditional chemotherapeutic agent depleted 50% of tumor infiltrating Gr1+/CD11b+ MDSCs without the impairment of T and B cell subsets, additionally cisplatin abrogated the immunosuppressive phenotype of the rest myeloid infiltrate in B16 melanoma model [144]. This evidence concerns the gene ITGAM and neoplasm.